Myotonic Disorders
📧 Sign up to get email alerts when something new happens for Myotonic Disorders.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-06-03EMA Authorised: Namuscla (Mexiletine hydrochloride) — Lupin Europe GmbH
Namuscla (mexiletine hydrochloride) by Lupin Europe GmbH has been authorised for myotonic disorders in the EU.
-
EMA approval · 2026-01-16EMA Authorised: Namuscla (Mexiletine hydrochloride) — Lupin Europe GmbH
The European Medicines Agency authorised Namuscla (mexiletine hydrochloride) for myotonic disorders under Lupin Europe GmbH, with orphan des…
-
CLINICAL_TRIALS research · 2025-07-25Clinical Trial Update: Open-label Extension Study in Paediatric Patients Who Have Completed the MEX-NM-301 Study. [NA]
Open-label extension study in paediatric patients who completed the MEX-NM-301 trial for myotonic disorders; the study is currently active b…
-
CLINICAL_TRIALS trial_result · 2013-03-06Clinical Trial Update: Characteristics of Nondystrophic Myotonias
This clinical trial update describes the characteristics of nondystrophic myotonias, including myotonia congenita.